Annual CFO
-$15.32 M
-$4.25 M-38.45%
December 31, 2023
Summary
- As of February 7, 2025, EPRX annual cash flow from operations is -$15.32 million, with the most recent change of -$4.25 million (-38.45%) on December 31, 2023.
- During the last 3 years, EPRX annual CFO has fallen by -$15.02 million (-4982.38%).
- EPRX annual CFO is now -4982.38% below its all-time high of -$301.40 thousand, reached on December 1, 2020.
Performance
EPRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$10.19 M
-$2.48 M-32.12%
September 1, 2024
Summary
- As of February 7, 2025, EPRX quarterly cash flow from operations is -$10.19 million, with the most recent change of -$2.48 million (-32.12%) on September 1, 2024.
- Over the past year, EPRX quarterly CFO has dropped by -$2.48 million (-32.12%).
- EPRX quarterly CFO is now -2967.89% below its all-time high of $355.30 thousand, reached on March 1, 2020.
Performance
EPRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$29.92 M
-$4.25 M-16.53%
September 1, 2024
Summary
- As of February 7, 2025, EPRX TTM cash flow from operations is -$29.92 million, with the most recent change of -$4.25 million (-16.53%) on September 1, 2024.
- Over the past year, EPRX TTM CFO has dropped by -$4.25 million (-16.53%).
- EPRX TTM CFO is now -8521.62% below its all-time high of $355.30 thousand, reached on March 1, 2020.
Performance
EPRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
EPRX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -38.5% | -32.1% | -16.5% |
| 3 y3 years | -4982.4% | -265.2% | -160.6% |
| 5 y5 years | -138.6% | -2967.9% | -8521.6% |
EPRX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -38.5% | at low | -265.2% | at low | -186.4% | at low |
| 5 y | 5-year | -4982.4% | at low | -2967.9% | at low | -8521.6% | at low |
| alltime | all time | -4982.4% | at low | -2967.9% | at low | -8521.6% | at low |
Eupraxia Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$10.19 M(+32.1%) | -$29.92 M(+16.5%) |
| Jun 2024 | - | -$7.71 M(+26.0%) | -$25.68 M(+15.5%) |
| Mar 2024 | - | -$6.12 M(+3.7%) | -$22.24 M(+7.5%) |
| Dec 2023 | -$15.32 M(+38.4%) | -$5.90 M(-0.8%) | -$20.68 M(+7.1%) |
| Sep 2023 | - | -$5.94 M(+39.2%) | -$19.32 M(+11.5%) |
| Jun 2023 | - | -$4.27 M(-6.5%) | -$17.33 M(+9.3%) |
| Mar 2023 | - | -$4.57 M(+0.8%) | -$15.85 M(+10.1%) |
| Dec 2022 | -$11.06 M | - | - |
| Dec 2022 | - | -$4.53 M(+14.5%) | -$14.40 M(+13.8%) |
| Sep 2022 | - | -$3.96 M(+41.7%) | -$12.65 M(+21.1%) |
| Jun 2022 | - | -$2.79 M(-10.2%) | -$10.45 M(-6.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$3.11 M(+11.5%) | -$11.13 M(-3.1%) |
| Dec 2021 | -$11.68 M(+3774.7%) | -$2.79 M(+59.3%) | -$11.48 M(+30.6%) |
| Sep 2021 | - | -$1.75 M(-49.6%) | -$8.79 M(+20.5%) |
| Jun 2021 | - | -$3.48 M(+0.3%) | -$7.30 M(+76.4%) |
| Mar 2021 | - | -$3.47 M(+3421.6%) | -$4.14 M(+1206.4%) |
| Dec 2020 | -$301.40 K(-92.3%) | -$98.40 K(-61.6%) | -$316.70 K(+45.1%) |
| Sep 2020 | - | -$256.20 K(-19.3%) | -$218.30 K(-676.0%) |
| Jun 2020 | - | -$317.40 K(-189.3%) | $37.90 K(-89.3%) |
| Mar 2020 | - | $355.30 K | $355.30 K |
| Dec 2019 | -$3.90 M(-39.3%) | - | - |
| Dec 2018 | -$6.42 M(+57.1%) | - | - |
| Dec 2017 | -$4.09 M | - | - |
FAQ
- What is Eupraxia Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Eupraxia Pharmaceuticals?
- What is Eupraxia Pharmaceuticals annual CFO year-on-year change?
- What is Eupraxia Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Eupraxia Pharmaceuticals?
- What is Eupraxia Pharmaceuticals quarterly CFO year-on-year change?
- What is Eupraxia Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Eupraxia Pharmaceuticals?
- What is Eupraxia Pharmaceuticals TTM CFO year-on-year change?
What is Eupraxia Pharmaceuticals annual cash flow from operations?
The current annual CFO of EPRX is -$15.32 M
What is the all time high annual CFO for Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals all-time high annual cash flow from operations is -$301.40 K
What is Eupraxia Pharmaceuticals annual CFO year-on-year change?
Over the past year, EPRX annual cash flow from operations has changed by -$4.25 M (-38.45%)
What is Eupraxia Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of EPRX is -$10.19 M
What is the all time high quarterly CFO for Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals all-time high quarterly cash flow from operations is $355.30 K
What is Eupraxia Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, EPRX quarterly cash flow from operations has changed by -$2.48 M (-32.12%)
What is Eupraxia Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of EPRX is -$29.92 M
What is the all time high TTM CFO for Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals all-time high TTM cash flow from operations is $355.30 K
What is Eupraxia Pharmaceuticals TTM CFO year-on-year change?
Over the past year, EPRX TTM cash flow from operations has changed by -$4.25 M (-16.53%)